Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Machiko Arita

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|August 25, 2011
[Four cases of respiratory infections caused by Legionella pneumophila serogroup 3]Akihiro Nishiyama, Tadashi Ishida, Youhei Kourogi, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary FibrosisSatoshi Konishi, Machiko Arita, Isao Ito, et al.
Histopathology|February 17, 2017
Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's diseaseYasuhiro Terasaki, Soichiro Ikushima, Shoko Matsui, et al.
Journal of Clinical Medicine|November 27, 2024
The Clinical Significance of Interstitial Pneumonia with Autoimmune Features in Cryptogenic Organizing Pneumonia: A Prospective Multicenter Observational StudyHisao Higo, Hirohisa Ichikawa, Yukako Arakawa, et al.
Respiratory Research|June 23, 2021
Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational studyTakafumi Niwamoto, Tomohiro Handa, Yuko Murase, et al.
Thorax|April 3, 2023
Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trialKensuke Kataoka, Osamu Nishiyama, Takashi Ogura, et al.
American Journal of Respiratory and Critical Care Medicine|January 10, 2020
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled TrialYasuhiro Kondoh, Arata Azuma, Yoshikazu Inoue, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|August 25, 2011
[Four cases of respiratory infections caused by Legionella pneumophila serogroup 3]Akihiro Nishiyama, Tadashi Ishida, Youhei Kourogi, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary FibrosisSatoshi Konishi, Machiko Arita, Isao Ito, et al.
Histopathology|February 17, 2017
Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's diseaseYasuhiro Terasaki, Soichiro Ikushima, Shoko Matsui, et al.
Journal of Clinical Medicine|November 27, 2024
The Clinical Significance of Interstitial Pneumonia with Autoimmune Features in Cryptogenic Organizing Pneumonia: A Prospective Multicenter Observational StudyHisao Higo, Hirohisa Ichikawa, Yukako Arakawa, et al.
Respiratory Research|June 23, 2021
Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational studyTakafumi Niwamoto, Tomohiro Handa, Yuko Murase, et al.
Thorax|April 3, 2023
Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trialKensuke Kataoka, Osamu Nishiyama, Takashi Ogura, et al.
American Journal of Respiratory and Critical Care Medicine|January 10, 2020
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled TrialYasuhiro Kondoh, Arata Azuma, Yoshikazu Inoue, et al.
Pageof 7